A ketogenic diet reduced stress on insulin-producing pancreatic cells in early-stage Type 2 diabetes patients by up to 56 percent compared to a low-fat diet, according to a 12-week study from the University of Alabama at Birmingham.
The study measured pancreatic strain using a biomarker ratio, not weight loss
Researchers tracked the proinsulin-to-C-peptide ratio (PICP), which rises when beta cells are overworked and release unprocessed insulin precursors. In the ketogenic group, this ratio dropped significantly both at rest and under metabolic stress, indicating relieved pancreatic strain. The low-fat diet group showed a smaller improvement, despite identical calorie control and stable body weight across both groups.
Participants ate strictly controlled, whole-food meals with extreme carb restriction
The ketogenic group received meals deriving just nine percent of energy from carbohydrates, while the low-fat group got 55 percent from carbs like bread and pasta. Sugar was nearly eliminated from both diets, and all food was provided by researchers to ensure adherence. Weight remained stable throughout, isolating the metabolic effect of macronutrient composition from weight loss.
This challenges the assumption that diabetes benefits from keto come only from weight reduction
Since participants did not lose weight, the improvement in beta-cell function suggests a direct physiological impact of very low carbohydrate intake on pancreatic stress. The findings imply that dietary composition alone can modulate early diabetes pathology, offering a non-pharmacological lever for disease management in the critical window after diagnosis.
Can a ketogenic diet reverse Type 2 diabetes?
The study did not assess reversal of diabetes, only short-term reduction in pancreatic stress. Long-term outcomes and durability of the effect beyond 12 weeks were not measured.
Is this diet safe for all people with diabetes?
The research focused only on early-stage Type 2 diabetes patients (diagnosed within 10 years). It did not include individuals with Type 1 diabetes, advanced Type 2 diabetes, or those on insulin therapy, so safety and efficacy in those groups remain unknown from this study.
